Biotech Lock-Up Expiration Hell Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (813)	7/22/2003 3:56:11 PM
From: Biomaven	Read Replies (2) of 1005

tuck, Not clear to me that they are in fact going beyond migraine. My guess is that this is going to be another version of a triptan/nsaid or a dopamine-blocker/nsaid. The NSAID market is very crowded, and I'm not sure where lornoxicam would fit in (which perhaps explains why they paid so little for it). Some indication that it might be good as an injectable as well as an oral drug, so that perhaps gives them another option. In general, a little strange given that nobody else (at least that I'm aware of) is developing new nsaids for the US market. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next